Williams WB, Wiehe K, Saunders KO, Haynes BF. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. J Int AIDS Soc. 2021;24(7):25831.

Google Scholar 

Zolla-Pazner S, Michael NL, Kim JH. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials. Lancet HIV. 2021;8(7):e449–52.

Article  Google Scholar 

Hanke T. New vector and vaccine platforms: mRNA, DNA, viral vectors. Curr Opin HIV AIDS. 2022;17(6):338–44.

Article  CAS  Google Scholar 

Vermund SH, Tique JA, Cassell HM, Pask ME, Ciampa PJ, Audet CM. Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr. 2013;63(1):12–25.

Article  Google Scholar 

Zhang, C., Vermund, S.H. Voluntary Medical Male Circumcision for HIV Prevention: a Global Overview. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00632-y.

Prodger JL, Galiwango RM, Tobian AAR, Park D, Liu CM, Kaul R. How Does Voluntary Medical Male Circumcision Reduce HIV Risk? Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00634-w.

• Agot K, Onyango, J, Ochillo M, Odoyo-June, E,  et al. VMMC Programmatic Successes and Challenges: Western Kenya Case Study. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00644-8. Arguably, VMMC has been most successful in western Kenya and the lessons learned can be informative for all of sub-Saharan Africa and other regions seeking to scale up VMMC programs.

• Mehta, S.D. The Effects of Medical Male Circumcision on Female Partners’ Sexual and Reproductive Health. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00638-6. It is not adequately appreciated the extent to which VMMC can benefit women.

Lucas T, Cooney C, Prainito A, Godfrey C, Kiggundu V, Thomas, AG, et al. Consolidated Overview of Notifiable Adverse Events in the U.S. President’s Emergency Plan for AIDS Relief’s Voluntary Medical Male Circumcision Program Through 2020. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00636-8.

Gao Y, Sun Y, Zheng W, Lin Y-F, Tian T, Li Y, et al. Risk Compensation in Voluntary Medical Male Circumcision Programs. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00635-9.

Gao Y, Yuan T, Zhan Y, Qian HZ, Sun Y, Zheng W, et al. Association between medical male circumcision and HIV risk compensation among heterosexual men: a systematic review and meta-analysis. Lancet Glob Health. 2021;9(7):e932–41.

Article  Google Scholar 

•  Lin Y, Gao Y, Sun Y, Turner D, Zou H, Vermund SH, et al. Does voluntary medical male circumcision reduce HIV risk in men who have sex with men? Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00637-7. Research sponsors should seek a definitive clinical trials answer to the extent to which MSM might benefit from circumcision.

Bershteyn A, Mudimu E, Platais I, Mwalili S, Zulu JE, et al. Understanding the evolving role of voluntary medical male circumcision as a public health strategy in Eastern and Southern Africa: opportunities and challenges. Curr HIV/AIDS Rep. 2022. https://doi.org/10.1007/s11904-022-00639-5.

Farley TM, Samuelson J, Grabowski MK, Ameyan W, Gray RH, Baggaley R. Impact of male circumcision on risk of HIV infection in men in a changing epidemic context – systematic review and meta-analysis. J Int AIDS Soc. 2020;23(6):e25490.

Article  Google Scholar 

• Peck, M.E., Lucas, T., Ong, K.S. et al. Defining the Global Research and Programmatic Agenda and Priority Actions for Voluntary Medical Male Circumcision for HIV Prevention. Curr HIV/AIDS Rep (2022). https://doi.org/10.1007/s11904-022-00640-y. Signposting future policy priorities helps both programmatic and investigative planning.

Aguolu OG, Malik AA, Ahmed N, Omer SB. Overcoming vaccine hesitancy for future COVID-19 and HIV vaccines: lessons from measles and HPV vaccines. Curr HIV/AIDS Rep. 2022;19(5):328–43.

Article  Google Scholar 

Tankwanchi AS, Jaca A, Ndlambe AM, Zantsi ZP, Bowman B, Garrison MM, et al. Non-COVID-19 vaccine hesitancy among migrant populations worldwide: a scoping review of the literature, 2000–2020. Expert Rev Vaccines. 2022;21(9):1269–87.

Article  CAS  Google Scholar 

Nanni A, Meredith S, Gati S, Holm K, Harmon T, Ginsberg A. Strengthening global vaccine access for adolescents and adults. Vaccine. 2017;35(49):6823–7.

Article  Google Scholar 

Guignard A, Praet N, Jusot V, Bakker M, Baril L. Introducing new vaccines in low- and middle-income countries: challenges and approaches. Expert Rev Vaccines. 2019;18(2):119–31.

Article  CAS  Google Scholar 

Gostin LO, Hodge JG Jr, Bloom BR, El-Mohandes A, Fielding J, Hotez P, et al. The public health crisis of underimmunisation: a global plan of action. Lancet Infect Dis. 2020;20(1):e11–6.

Article  Google Scholar 

Sauer M, Vasudevan P, Meghani A, Luthra K, Garcia C, Knoll MD, Privor-Dumm L. Situational assessment of adult vaccine preventable disease and the potential for immunization advocacy and policy in low- and middle-income countries. Vaccine. 2021;39(11):1556–64.

Article  Google Scholar 

Levin A, Boonstoppel L, Brenzel L, Griffiths U, Hutubessy R, Jit M, et al. WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. BMC Med. 2022;20(1):88.

Article  Google Scholar